The range of diseases in which intravenous immunoglobulin (IVIG) is effective has expanded
significantly since its initial use in primary antibody deficiency. There are at present at least …

Objectives: Tocilizumab (TCZ), an IL-6 receptor antagonist, is used in the treatment of severe
COVID-19 caused by infection with SARS-CoV-2. However, unintended consequences of …

… Hollander, who keptme straight on autoimmunity and toleranceas well asnew basic
concepts, Meilyn Hew for reading the practical chapter and Siraj Misbah for making sure thatmy …

Causes of secondary antibody deficiency include B-cell lymphoproliferative disease, notably
chronic lymphocytic leukaemia and multiple myeloma, protein losing states, disorders of …

The role of clinical pathologists or laboratory-based physicians is being challenged on several
fronts—exponential advances in technology, increasing patient autonomy exercised in …

The role of CD1a‐reactive T cells in human allergic disease is unknown. We have previously
shown that circulating CD1a‐reactive T cells recognize neolipid antigens generated by bee …

Intravenous immunoglobulin (IVIG) is the first‐line therapy for multifocal motor neuropathy (MMN).
This open‐label multi‐centre study (NCT00701662) assessed the efficacy, safety, and …

Objectives The association of B cell targeted therapies with development of
hypogammaglobulinaemia and infection is increasingly recognized. Our aim was to develop …

Background Autoimmune pancreatitis (AIP) is recognised as an end organ manifestation of
the systemic condition known as IgG4-sclerosing disease. One major characteristic of this …

Intravenous Ig (IVIg) is well established as replacement therapy in primary immunodeficiencies
at doses of 0.2 to 0.6 g/kg/mo. It is considered safe with minor side effects usually related …